Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.9 (
ribonuclease
)
6,589
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mast cells produce substances with antiinflammatory properties in addition to their capacity to release proinflammatory mediators. To further probe the antiinflammatory aspect of mast-cell function we investigated the ability of human mast cells (huMCs) to produce interleukin (IL)-1 receptor antagonist (
IL-1ra
) in response to high-affinity Fc receptor for immunoglobulin E (Fcalpha RI) aggregation, and examined
IL-1ra
in bronchoalveolar lavage fluid (BALF) to determine whether it might be of mast-cell origin. Using a
ribonuclease
protection assay, flow cytometry, and enzyme-linked immunosorbent assay (ELISA),
IL-1ra
message and protein were found to be constitutively expressed in cultured huMCs. Upon stimulation through Fcalpha RI,
IL-1ra
message was upregulated in huMCs and
IL-1ra
protein secreted from cultured huMCs and isolated human lung mast cells. By immunoblot analysis, huMCs were found to produce the 17-kD form of
IL-1ra
and the presence of
IL-1ra
in human lung mast cells was confirmed by immunohistochemistry. In BALF obtained from allergic asthmatic subjects,
IL-1ra
production increased after specific antigen challenge, with the 17-kD isoform of
IL-1ra
predominating. These findings demonstrate that huMCs produce and release
IL-1ra
after Fcalpha RI aggregation, which may contribute to a local inhibition of IL-1-dependent effects on inflammation in the lung.
...
PMID:Secretion of interleukin-1 receptor antagonist from human mast cells after immunoglobulin E-mediated activation and after segmental antigen challenge. 1172 93